RE:RE:RE:RE:Poor trial design, terrible sites, pitiful managementThe best news is that they have decided on a dose.
That means the DSMB reviewed initial data and made that decision.
Good news is they could have reviewed it and decided not to continue. It must mean that the higher dose has efficacy beyond the placebo and lower dose.
What we need as investors is real recruitment! With 40 sites this trial should be fully rectruited in 30 days.
M. Frank, pick up your socks and recruit some real sites here. Stop playing CEO and be one! How about a site advertising the trial, just one of the 41?
RandomGuy1 wrote: Just trolling a bit.
But what's your honest opinion on this? Is this considered good news for us hoping or is it lacklustre? Does this imply that they have been performing the trials and thus far, no serious side effects have occurred? How do you interpret this?
To date, the ongoing Study has not seen any serious adverse events or safety concerns that required the DSMB to be notified or take action on. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations.